Levomilnacipran (Fetzima) coverage/medical necessity policy
Defines clinical and administrative criteria for initial and continued authorization of levomilnacipran (Fetzima) for major depressive disorder in adults within Centene-affiliated health plans, including required trials of alternative antidepressants, dosing limits, exclusions (e.g., fibromyalgia), and documentation/approval duration.
3Q 2025 annual review: clarified failure of two antidepressants from at least two different drug classes and added step therapy bypass for IL HIM per IL HB 5395; updated therapeutic alternatives.
3Q 2024 annual review: revised continued therapy to allow continuity of care for antidepressants; added Wellbutrin SR to therapeutic alternatives and clarified fluvoxamine used in depression is off-label.
3Q 2023 annual review: added vilazodone (generic Viibryd) to list of redirect options and added redirection bypass for states with limitations on step therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.